Alnylam Pharmaceuticals (NASDAQ: ALNY) — Perfil da empresa, notícias e dados financeiros
Alnylam Pharmaceuticals develops RNA interference-based therapies for rare genetic diseases, focusing on innovative genetic medicines.
Alnylam Pharmaceuticals
Alnylam Pharmaceuticals is a biopharmaceutical company focused on the discovery, development, and commercialization of RNA interference therapeutics. Headquartered in Cambridge, Massachusetts, the company utilizes lipid nanoparticle and N-acetylgalactosamine conjugate delivery technologies to target specific messenger RNAs, silencing disease-causing genes before targeted proteins are synthesized. Its commercial product portfolio includes treatments for transthyretin-mediated amyloidosis, acute hepatic porphyria, and primary hyperoxaluria type 1, alongside out-licensed therapies for hypercholesterolemia. The company operates research, clinical development, and specialized manufacturing facilities in the United States while advancing an active pipeline across cardiovascular, central nervous system, and metabolic diseases.
Resumo
Operações
Produtos e/ou serviços de Alnylam Pharmaceuticals
- Transthyretin Amyloidosis Therapeutics: Commercialization of RNA interference therapeutics targeting transthyretin amyloidosis, delivered via subcutaneous and intravenous administration to silence pathogenic transthyretin protein production in adult patients diagnosed with hereditary polyneuropathy and cardiomyopathy across global healthcare markets.
- Acute Hepatic Porphyria Therapeutics: Development and commercial delivery of targeted RNA interference therapy designed to prevent or reduce hepatic aminolevulinic acid synthase 1 expression, addressing recurrent attacks and severe disease manifestations in adult and adolescent patients.
- Primary Hyperoxaluria Therapeutics: Subcutaneously administered RNA interference treatment targeting hydroxyacid oxidase 1 in the liver to reduce plasma oxalate levels, approved for pediatric and adult patients suffering from primary hyperoxaluria type 1.
- Out-Licensed Partnered Programs: Strategic pharmaceutical partnerships providing out-licensed RNA interference candidates, including a liver-targeted therapeutic for hypercholesterolemia developed in collaboration with major global biopharmaceutical partners, generating royalty and milestone revenues.
- RNAi Clinical Pipeline: Research and clinical-stage development of therapeutic pipeline candidates using lipid nanoparticle and conjugate delivery platforms, expanding gene-silencing applications into prevalent cardiovascular, central nervous system, ocular, and metabolic disease indications.
- Commercial Manufacturing Infrastructure: Biopharmaceutical manufacturing and supply chain operations, featuring specialized production facilities in Massachusetts that produce bulk synthetic oligonucleotide active pharmaceutical ingredients and therapeutic formulations for global clinical trials and commercial distribution.
equipe executiva do Alnylam Pharmaceuticals
- Yvonne L. GreenstreetCEO & Director
- Phillip A. SharpCo-Founder, Member of the Scientific Advisory Board
- Jeffrey V. PoultonCFO & Executive VP
- Bryan Andrew SupranChief Legal Officer
- Pushkal P. GargExecutive VP & Chief Research & Development Officer
- Tolga TangulerExecutive VP & Chief Commercialization Officer
- Timothy J. MainesChief Technical Operations & Quality Officer
- Kevin Joseph FitzgeraldExecutive VP, Chief Scientific Officer and Head of Early Research & Early Development
- Joshua BrodskyVice President of Investor Relations
- Piyush SharmaChief Ethics & Compliance Officer
Últimas notícias sobre a Alnylam Pharmaceuticals
Principais indicadores financeiros
Resultados divulgados pela Alnylam Pharmaceuticals, em USD.
- Cap. de mercado
- 30,3 bi
- Receita (TTM)
- 4,8 bi
- P/L
- 38.2
- LPA (diluído, TTM)
- 5.9
- Dividend yield
- —
- Margem de lucro
- 16.1%
| Fim do ano fiscal | Receita | Resultado operacional | Lucro líquido |
|---|---|---|---|
| 3,7 bi | 501,6 mi | 313,7 mi | |
| 2,2 bi | -176,9 mi | -278,2 mi | |
| 1,8 bi | -282,2 mi | -440,2 mi | |
| 1 bi | -785,1 mi | -1,1 bi |